Human CD276/B7-H3 (DS-5573a) Antibody is a research-grade biosimilar monoclonal antibody. It is a human IgG antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
CD276 antigen (B7-H3) is a ~57 kDa protein. May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. CD276 is the therapeutic target of omburtamab (clinical).
Product Name:
Human CD276/B7-H3 (DS-5573a) Antibody
SKU:
GXBS00944
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Clone:
DS-5573a
Target:
4Ig-B7-H3
Isotype:
IgG
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Synonyms:
DS-5573a, DS5573a, DS5573a
Biological Activity:
DS-5573a (1 ug/mL) binds to the IgC1 and IgC2 domains of human B7-H3 expressed in transfected CHO-K1 cells [1]. The K d value of DS-5573a binding to recombinant human 4IgB7-H3 is 1.8 nM, and the K d value of its binding to recombinant human 2IgB7-H3 is 11 nM [1]. DS-5573a (0.01-1000 ng/mL; 4 h) exerts potent, B7-H3-dependent antibody-dependent cell-mediated cytotoxicity against NCI-H322, MDA-MB-231 and COLO205 cells via human peripheral blood mononuclear cells (PBMC), while exhibits only minimal activity against B7-H3-negative CCRF-CEM cells [1]. DS-5573a (1-10000 ng/mL; 3 h) exerts B7-H3-dependent antibody-dependent cellular phagocytosis (ADCP) activity against NCI-H322, MDA-MB-231 and COLO205 cells via human monocyte-derived macrophages, but shows no activity against B7-H3-negative CCRF-CEM cells [1]. Cell Cytotoxicity Assay [1] Cell Line: NCI-H322, MDA-MB-231, and COLO205 cells Concentration: 0.01, 0.1, 1, 10, 100, 1000 ng/mL Incubation Time: 4 h Result: Exerted potent, B7-H3-dependent ADCC activity against NCI-H322, MDA-MB-231, and COLO205 cells via human PBMCs. DS-5573a (0.003-3 mg/kg; i.p.; once a week; 5 weeks) exhibits dose-dependent, statistically significant antitumor activity against MDA-MB-231 breast adenocarcinoma in female SCID mice, with significant efficacy observed at doses as low as 0.03 mg/kg and maximal activity at 0.3 mg/kg and 3 mg/kg [1].
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
